Thermo Fisher Scientific reported its third-quarter 2024 results, beating earnings per share (EPS) estimates but missing revenue expectations. The company raised the lower end of its full-year EPS guidance, now expecting adjusted EPS to be in the range of $21.35 to $22.07. This marks the third time this year that Thermo Fisher has adjusted its profit forecast, driven by strong demand for its drug development tools and services. Despite the revenue miss, the company remains optimistic about future growth, particularly in its China business. The CEO highlighted strong financial results and sequential improvement in growth. Thermo Fisher's stock dropped by 0.6% in pre-market trading.